Enzyme-Responsive Therapeutic Vectors for Selective Cancer Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, lack selectivity and often cause severe side effects due to non-specific toxicity, leading to insufficient drug concentration at tumor sites and increased risk of cellular resistance.
Innovation Solution
Development of therapeutic vectors and prodrugs that utilize enzyme-responsive systems, specifically targeting the tumor microenvironment with glucuronyl radicals to release anticancer agents like dolastatin derivatives, which are activated by β-glucuronidase enzymes present in tumors, ensuring selective drug delivery and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat cancer, then it can kill tumor cells, but it causes severe side effects due to non-specific toxicity to normal tissues
Solution Approach 1:
The patent segments the chemotherapy approach into two distinct components: a targeting unit that specifically recognizes tumor cells and a cytotoxic unit that delivers the anticancer agent. This segmentation allows the drug to be selectively delivered to tumor cells while sparing normal tissues, thereby maintaining anticancer efficacy while reducing toxicity to healthy cells
Solution Approach 2:
The patent introduces a targeting unit as an intermediary component that mediates between the cytotoxic agent and the tumor cell. This targeting unit (such as antibodies or ligands) specifically binds to tumor-associated markers, acting as a mediator that directs the cytotoxic unit to the correct target while preventing non-specific interaction with normal cells
2Reliability
If the amount of chemotherapy drug is increased to achieve lethal concentration at tumor site, then treatment efficacy improves, but side effects on normal tissues increase
Solution Approach 1:
The patent applies local quality by concentrating the cytotoxic effect specifically at the tumor site through the targeting unit. The drug complex is designed to accumulate and activate preferentially in the tumor microenvironment, creating a localized high concentration of anticancer agent at the target site while maintaining low concentrations in normal tissues, thus achieving high treatment efficacy without proportionally increasing systemic toxicity
3Reliability
If conventional drug delivery systems targeting cell surface specificities are used, then selective delivery is achieved, but heterogeneity of cancer tissues reduces effectiveness
Solution Approach 1:
The patent enhances universality by designing a dual-component system where the targeting unit can recognize multiple tumor-associated markers and the cytotoxic unit provides the anticancer activity. This multi-functional design allows the system to effectively target heterogeneous tumor cells that may express different markers, as the targeting unit can bind to various tumor-specific antigens while delivering the same cytotoxic payload
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the selective release of anticancer agents within the tumor microenvironment, improving treatment efficacy while minimizing side effects on healthy tissues and reducing cellular resistance.
Implementation Method 1
activation of the trigger leads to the release of the active drug selectively in the intracellular medium
Implementation Method 2
enzymatic or a chemical trigger that can be activated exclusively in cancerous tissues to induce the release of the drug
Data Source
AI summary
The present invention relates to a compound having the following formula (I):as well as the corresponding prodrugs, pharmaceutical compositions comprising said compounds, in particular for treating cancer.